

5. PCT International Publication No. WO 03/012111 A2, published February 13, 2003;
6. PCT International Publication No. WO 02/074921 A2, published September 26, 2002;
7. Koppi T. et al., "CMRF-44 Antibody-Mediated Depletion of Activated Human Dendritic Cells: A Potential Means for Improving Allograft Survival", *Transplantation* 75(10):1723-1730 (2003); and
8. Manome H. et al., "Dexamethasone and Cyclosporin A Affect the Maturation of Monocyte-Derived Dendritic Cells Differently", *Int. Arch Allergy & Immunology* 122(1):76-84 (2000).

The references were cited in an International Search Report dated September 26, 2003 received from the Australian Patent Office. Applicants are submitting copies of the above-cited references. Applicants previously submitted a copy of the International Search Report on February 15, 2005. The relevance of the above-identified references has been described in the International Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343

XZ:dg

**LIST OF PRIOR ART
CITED BY APPLICANT***(Use several sheets if necessary)***Atty. Docket No. (Optional)**

18655

Application Number

10/524,716

Applicant(s)

Masato Kato, et al.

Filing Date

February 16, 2006

Group Art Unit

1644

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 01/78768 A2	10/25/01	PCT			✓	
		WO 01/40308 A2	6/7/01	PCT			✓	
		WO 99/24554	5/20/99	PCT			✓	
		WO 02/080952 A2	10/17/02	PCT			✓	
		WO 03/012111 A2	2/13/03	PCT			✓	
		WO 02/074921 A2	9/26/02	PCT			✓	

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

		Koppi T. et al., "CMRF-44 Antibody-Mediated Depletion of Activated Human Dendritic Cells: A Potential Means for Improving Allograft Survival", <i>Transplantation</i> 75(10):1723-1730 (2003)
		Manome H. et al., "Dexamethasone and Cyclosporin A Affect the Maturation of Monocyte-Derived Dendritic Cells Differently", <i>Int. Arch Allergy & Immunology</i> 122(1):76-84 (2000)

EXAMINER**DATE CONSIDERED**

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

UNITED STATES PATENT APPLICATION DISPATCH SHEET

TO: Docketing Department

FROM: **DEB GERBER**

Mail Stop PCT

The following communication(s) was sent to the United States Patent and Trademark Office on

10/25/00

- ☐ New Patent Application with transmittal (in duplicate)
____ Divisional ____ Continuation ____ CPA ____ CIP ____ PCT
- ☐ New Provisional Patent Application with transmittal (in duplicate)
- ☐ Amendment with transmittal (in duplicate)
- ☐ Preliminary Amendment with transmittal (in duplicate)
- ☒ Information Disclosure Statement with transmittal (in duplicate)
☒ PTO-1449 (8) copies of cited references _____ Search Report
- ☐ Petition for Extension of Time ____ 1-month ____ 2-months ____ 3-months
____ 4-months ____ 5-months
- ☐ Notice of Appeal (in duplicate)/or Brief on Appeal (in triplicate) (circle one)
- ☐ Executed Assignment with Recordal Cover Sheet ____ check
- ☐ Response to Notice to File Missing Parts with executed Declaration
- ☐ Sequence Listing, Statement, Copy of Notice to Comply, Response to
Notice to Comply, Computer Disk w/ Sequence in ASCII
- ☐ Issue Fee Transmittal (in duplicate)
- ☐ Transmittal of Formal Drawings (Figures _____, # of sheets _____)
- ☐ Claim of Priority ____ (herewith) ____ (in due course)
____ (Certified Priority Document)
- ☐ Deposit Account No. charged _____ Amount being charged \$ _____
- ☐ Check in the amount of \$ _____
- ☒ Certificate of Mailing ☒ first class _____ Express

Other:

Client No: 536 Client Name: Adrian Collison

Serial No.: 10/524,714 Docket No.: 18655 Due Date: _____

Attorney Preparing Paper: X2 Attorney Signing Paper: X2

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 18655	
In Re Application Of: Masato Kato, et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/524,716	February 16, 2006	Amy E. Juedes	23389	1644	8342	
Title: METHOD OF IMMUNOMODULATION						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
37 CFR 1.97(b)						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
37 CFR 1.97(c)						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);						
OR						
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).						

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 18655	
In Re Application of: Masato Kato, et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/524,716	February 16, 2006	Amy E. Juedes	23389	1644	8342	
Title: METHOD OF IMMUNOMODULATION						

Payment of Fee
 (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

☐ A check in the amount of _____ is attached.
☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP
 as described below.

☐ Charge the amount of _____
☒ Credit any overpayment.
☒ Charge any additional fee required.

☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on


October 25, 2006
(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**



 Signature

Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

Dated: **October 25, 2006**